39 results about "Giant cell" patented technology

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Provided is a promoter having high activity in an activated T-cell. The promoter comprises, from 5′-end to 3′-end, a CMV enhancer, an IFNγ promoter, and a long terminal repeat sequence from human T-cell leukemia virus that are connected in sequence. The promoter exhibits greater activity in an activated immune cell than the existing promoters and is low in activity or inactive in other non-immune cells.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and / or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

The invention provides an HLA allele difference quantification method and application thereof. The HLA allele difference quantification method comprises the following steps: obtaining typing results of HLA alleles of a recipient and a donor; combining the typing results of the recipient and the donor in pairs to obtain four groups of combined typing results; respectively decoding typing results of the four groups of combinations into amino acid sequences; respectively calculating the HED value of the typing result of each group of combination; calculating the sum of the HED values of the typing results of the four groups of combinations to obtain HEDHLA allele values of the recipient and the donor; and according to the HEDHLA allele value, quantifying the difference between the recipient and the donor in the HLA allele. The HLA allele difference quantification method is used for predicting the chronic graft versus host disease risk, the acute graft versus host disease risk, the recurrence risk, the cytomegalovirus infection risk and the like of hematopoietic stem cell transplantation, and has important guiding significance on selection of prognosis treatment schemes of target objects.

The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.

Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.

The present application provides, inter alia, methods of treating tenosynovial giant cell tumor in a patient in need thereof, wherein the methods comprise administering to the patient a compound represented by Formula (I). Formula (I).

Provided are methods of digital therapeutics for individuals with benign connective tissue tumor. More specifically, the digital therapeutics are designed to modulate Tenosynovial Giant Cell Tumor (TGCT), on a standalone basis or by combining them with pharmaceutical drugs such as CSF1R inhibitors.

The invention provides a recombinant oncolytic adenovirus vector for expressing human IL-2, 4-1BBL and membrane type IL-21 proteins as well as a construction method and application thereof, and the method comprises the following steps: inserting two expression cassettes into an E1 region of an adenovirus, namely expression cassettes of IL-2, 4-1BBL and membrane type IL-21 genes regulated by a human cytomegalovirus broad-spectrum enhancer / promoter respectively, and an expression cassette of an E1 gene regulated by a tumor tissue or cell specific telomerase promoter. And co-transfecting HEK 293 cells by using the constructed double-expression cassette shuttle plasmid and an adenovirus skeleton plasmid to obtain the recombinant oncolytic adenovirus vector. The recombinant oncolytic adenovirus vector provided by the invention can efficiently express IL-2, 4-1BBL and membrane type IL-21, and after intratumor injection, the infiltration and activity of natural killer cells in a tumor microenvironment can be effectively improved, the tumor immunosuppression microenvironment is improved, and the antitumor activity is enhanced.

The present invention relates to a scalable process for the purification of human cytomegalovirus particles from cell culture medium. In particular, the process involves a two step chromatography process starting with an anion exchange chromatography step followed by a polishing chromatography step selected from mixed mode chromatography or cation exchange chromatography.

The present invention relates to imidazo[4,5-c]pyridine derivatives of formula (I) as SIK modulators for treating or preventing rheumatoid arthritis, juvenile idiopathic arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, giant cell arteritis, inflammatory bowel disease (IBD), atherosclerosis, type 2 diabetes or glomerulonephritis. TIFF2025521780000065.tif58161

The present disclosure relates to methods of treating giant cell arteritis (GCA) using an IL-17 antagonist (e.g., Jukoulikumab). Also disclosed herein are uses of IL-17 antagonists (e.g., IL-17 antibodies, such as Jiukumab) for the treatment of GCA patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a joint that is impacted by a disease that is treatable with CSF1 / CSF1R inhibition and / or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Disclosed herein are CMV-specific CARs. In some embodiments. the present invention is directed to a method of treating, reducing, or inhibiting an infection by a cytomegalovirus in a subject, which comprises administering to the subject (a) an expression vector that encodes a CMV-specific CAR as described herein, or (b) one or more cells that are transduced with the expression vector.

T cells expressing a chimeric antigen receptor and a T cell receptor specific for CMV (bi-specific T cells) are described as a methods for using such cells in immunotherapy. In the immunotherapy methods, the recipient can be exposed to a CMV vaccine in order to expand and / or stimulate the be-specific T cells.

CD8 + T cells comprising multispecific T-cell receptors and methods for making the same are provided.SOLUTION: A method of generating CD8 + T-cells comprising multispecific T-cell receptors (TCRs), the method comprising: (a) administering to a subject a recombinant cytomegalovirus (CMV) vector comprising a first heterologous antigen-encoding nucleotide sequence; (b) identifying a first CD8 + TCR from a first set of the CD8 + T-cells; (c) administering to the subject a second heterologous antigen-encoding nucleotide sequence; (d) isolating one or more CD8 + T-cells from a second set of the CD8 + T-cells; (e) identifying a second CD8 + TCR from the second set of CD8 + T cells; (f) transfecting a third set of CD8 + T cells with an expression vector; and (g) selecting one or more of the third CD8 + TCRs having the highest avidity for a particular peptide of interest.SELECTED DRAWING: None

The invention provides bidirectional expression vectors comprising Chinese hamster ovary elongation factor 1-α (CHEF1) transcriptional regulatory DNA elements, a gene of interest (GOI), a minimal cytomegalovirus (minCMV) and a selectable marker (SM) and / or a human adenovirus tripartite leader (AdTPL) sequence. The invention also provides method for increasing heterologous protein expression in a host cell comprising culturing the host cell the bidirectional expression vector(s).

To provide a biocompatible membrane composite capable of providing an environment capable of mitigating or controlling a foreign body reaction.SOLUTION: The membrane composite includes a conformable layer and a vascularizing layer. A reinforcing component can optionally be included to provide support to the biocompatible membrane composite invivo and prevent distortion of the membrane composite. The relief layer may be coupled or attached to the implantable device and / or the cell system. The biocompatible membrane composite can be used as a surface layer for implantable devices or cell systems that require vascularization for function but require protection from a host immune response, such as the formation of foreign body giant cells. The biocompatible membrane composite can partially or completely cover the exterior of the implantable device or cell system. The relief layer is positioned between the implantable device or bioactive scaffold and the vascularizing layer.SELECTED DRAWING: Figure 7

The present invention relates to a polypeptide composition, comprising a nucleic acid encoding a mutant pp65 polypeptide, the nucleic acid being mRNA, viral RNA, or replicon RNA. The composition is capable of expressing the mutant pp65 polypeptide in vivo, eliciting a specific humoral or cellular immune response against the pp65 polypeptide, and producing an effector cell having a tumor cell killing effect and a specific antibody.

The present disclosure is directed to methods for treating giant cell arteritis (GCA) using upadacitinib.

# imgabs0. The present invention relates to imidazo [4, 5-c] pyridine derivatives of formula (I) as SIK modulators for use in the treatment or prevention of rheumatoid arthritis, juvenile rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, giant cell vasculitis, inflammatory bowel disease (IBD), atherosclerosis, type 2 diabetes or glomerulonephritis.

Oligomer nucleotides, compositions, methods, kits, and uses are provided for detecting or quantifying a Human Cytomegalovirus virus 1 (CMV (human herpesvirus 5, HHV5) nucleic acid, e.g., using nucleic acid amplification and hybridization assays. Multiphase amplification of a CMV target sequence is also described. The oligomer nucleotides, compositions, methods, kits, and uses can be used to amplify and / or detect the UL56 gene of CMV.

The present disclosure relates to methods for treating giant cell arteritis (GCA), using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating GCA patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Provided are methods of digital therapeutics for individuals with benign connective tissue tumor. More specifically, the digital therapeutics are designed to modulate Tenosynovial Giant Cell Tumor (TGCT), on a standalone basis or by combining them with pharmaceutical drugs such as CSF1R inhibitors.

The present invention provides binding molecules having one or more of (preferably all of) highly specific binding to the US28 protein of human cytomegalovirus (HCMV), very low levels of non-specific binding to healthy (non-infected) cells, and / or a strain-agnostic binding ability, as well as nucleic acid molecules encoding the said binding molecules. The binding molecules are designed to bind to a newly-identified epitopic region within extracellular domain 1 (ECD1) of a US28 protein of human cytomegalovirus (HCMV), the first of the four extracellular domains presented by US28, corresponding to positions 1 to 37 of the US28 protein sequence as defined by SEQ ID NO:5. The binding molecules of the present invention have been demonstrated to have excellent binding properties, including particular binding specificity for aggressive and / or metastasizing HCMV-infected cancers, including breast cancers. In certain preferred embodiments, the binding molecule is selected from an antibody (including, for example, a BiTE antibody) and a chimeric antigen receptor (CAR), or functional variants, fragments, fusion proteins, and / or conjugates thereof. Also provided are cells expressing said binding molecules, such as CAR-expressing cells, including CAR-T cells, CAR-NK cells, and CAR-M cells.